DK1470155T3 - Pluripotensbestemmende faktorer og anvendelser deraf - Google Patents

Pluripotensbestemmende faktorer og anvendelser deraf

Info

Publication number
DK1470155T3
DK1470155T3 DK03734758T DK03734758T DK1470155T3 DK 1470155 T3 DK1470155 T3 DK 1470155T3 DK 03734758 T DK03734758 T DK 03734758T DK 03734758 T DK03734758 T DK 03734758T DK 1470155 T3 DK1470155 T3 DK 1470155T3
Authority
DK
Denmark
Prior art keywords
pluripotency
maintain
factors
determining factors
applications
Prior art date
Application number
DK03734758T
Other languages
English (en)
Inventor
Ian Chambers
Austin Gerard Smith
Original Assignee
Univ Edinburgh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Edinburgh filed Critical Univ Edinburgh
Application granted granted Critical
Publication of DK1470155T3 publication Critical patent/DK1470155T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5073—Stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Wood Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
DK03734758T 2002-01-30 2003-01-30 Pluripotensbestemmende faktorer og anvendelser deraf DK1470155T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0202149.1A GB0202149D0 (en) 2002-01-30 2002-01-30 Pluripotency determining factors and uses thereof

Publications (1)

Publication Number Publication Date
DK1470155T3 true DK1470155T3 (da) 2006-07-24

Family

ID=9930054

Family Applications (2)

Application Number Title Priority Date Filing Date
DK03734758T DK1470155T3 (da) 2002-01-30 2003-01-30 Pluripotensbestemmende faktorer og anvendelser deraf
DK06005029T DK1698639T3 (da) 2002-01-30 2003-01-30 Pluripotensbestemmende faktorer og anvendelser deraf

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK06005029T DK1698639T3 (da) 2002-01-30 2003-01-30 Pluripotensbestemmende faktorer og anvendelser deraf

Country Status (11)

Country Link
US (2) US7687266B2 (da)
EP (2) EP1698639B1 (da)
JP (1) JP2005536183A (da)
KR (1) KR20040093699A (da)
CN (1) CN1646562A (da)
AT (2) ATE393167T1 (da)
DE (2) DE60320599T2 (da)
DK (2) DK1470155T3 (da)
ES (1) ES2308616T3 (da)
GB (1) GB0202149D0 (da)
WO (1) WO2003064463A2 (da)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4268169B2 (ja) * 2003-01-31 2009-05-27 伸弥 山中 胚性幹細胞の自己複製決定因子
US20060288431A1 (en) * 2003-02-13 2006-12-21 Norio Nakatsuji Marker for undifferentiated state of cell and composition and method for separation and preparation of stem cells
ITRM20030376A1 (it) 2003-07-31 2005-02-01 Univ Roma Procedimento per l'isolamento e l'espansione di cellule staminali cardiache da biopsia.
US7682828B2 (en) 2003-11-26 2010-03-23 Whitehead Institute For Biomedical Research Methods for reprogramming somatic cells
US20090018059A1 (en) * 2004-09-03 2009-01-15 Agency For Science, Technology And Research Method for maintaining pluripotency of stem/progenitor cells
US8192988B2 (en) 2004-10-22 2012-06-05 University Of Central Florida Research Foundation, Inc. Methods for increasing potency of adult mesenchymal stem cells
US11660317B2 (en) 2004-11-08 2023-05-30 The Johns Hopkins University Compositions comprising cardiosphere-derived cells for use in cell therapy
US8759090B2 (en) * 2006-10-30 2014-06-24 University Of Central Florida Research Foundation, Inc. Stem cell banking system
GB0701062D0 (en) * 2007-01-19 2007-02-28 Evocell Ltd Biological materials and uses thereof
EP2137296A2 (en) * 2007-03-23 2009-12-30 Wisconsin Alumni Research Foundation Somatic cell reprogramming
MX348010B (es) 2007-04-07 2017-05-23 Whitehead Inst Biomedical Res Reprogramacion de celulas somaticas.
US20120282229A1 (en) * 2007-08-01 2012-11-08 Christian Kannemeier Non-viral delivery of transcription factors that reprogram human somatic cells into a stem cell-like state
US7615374B2 (en) 2007-09-25 2009-11-10 Wisconsin Alumni Research Foundation Generation of clonal mesenchymal progenitors and mesenchymal stem cell lines under serum-free conditions
EP3112456A1 (en) 2008-06-04 2017-01-04 Cellular Dynamics International, Inc. Methods for the production of ips cells using non-viral approach
US9497943B2 (en) 2008-06-13 2016-11-22 Whitehead Institute For Biomedical Research Nucleic acid constructs encoding reprogramming factors linked by self-cleaving peptides
KR101773345B1 (ko) 2008-08-12 2017-08-31 셀룰러 다이내믹스 인터내셔널, 인코포레이티드 ｉＰＳ 세포의 생산 방법
US9175079B2 (en) * 2010-01-29 2015-11-03 The Board Of Trustees Of The Leland Stanford Junior University Depletion of teratoma-forming pluripotent stem cells
US9845457B2 (en) 2010-04-30 2017-12-19 Cedars-Sinai Medical Center Maintenance of genomic stability in cultured stem cells
US9249392B2 (en) 2010-04-30 2016-02-02 Cedars-Sinai Medical Center Methods and compositions for maintaining genomic stability in cultured stem cells
US8497124B2 (en) 2011-12-05 2013-07-30 Factor Bioscience Inc. Methods and products for reprogramming cells to a less differentiated state
RU2691027C2 (ru) 2011-12-05 2019-06-07 Фэктор Байосайенс Инк. Способы и препараты для трансфекции клеток
WO2013184527A1 (en) 2012-06-05 2013-12-12 Capricor, Inc. Optimized methods for generation of cardiac stem cells from cardiac tissue and their use in cardiac therapy
EP2882445B1 (en) 2012-08-13 2019-04-24 Cedars-Sinai Medical Center Exosomes and micro-ribonucleic acids for tissue regeneration
RU2711249C2 (ru) 2012-11-01 2020-01-15 Фэктор Байосайенс Инк. Способы и продукты для экспрессии белков в клетках
CN103609526B (zh) * 2013-10-16 2015-10-07 中国科学院生物物理研究所 线粒体蛋白质翻译因子Guf1在雄性不育研究中的应用
EP4249036A3 (en) 2014-01-31 2023-10-25 Factor Bioscience Inc. Methods and products for nucleic acid production and delivery
US11357799B2 (en) 2014-10-03 2022-06-14 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy
CA2976376A1 (en) 2015-02-13 2016-08-18 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
WO2017123662A1 (en) 2016-01-11 2017-07-20 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of heart failure with preserved ejection fraction
US11351200B2 (en) 2016-06-03 2022-06-07 Cedars-Sinai Medical Center CDC-derived exosomes for treatment of ventricular tachyarrythmias
US10576167B2 (en) 2016-08-17 2020-03-03 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
WO2018057542A1 (en) 2016-09-20 2018-03-29 Cedars-Sinai Medical Center Cardiosphere-derived cells and their extracellular vesicles to retard or reverse aging and age-related disorders
WO2018167283A1 (en) 2017-03-17 2018-09-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling
JP7336769B2 (ja) 2017-04-19 2023-09-01 シーダーズ―シナイ メディカル センター 骨格筋ジストロフィーを治療する方法及び組成物
EP3727351A4 (en) 2017-12-20 2021-10-06 Cedars-Sinai Medical Center MODIFIED EXTRACELLULAR VESICLES FOR IMPROVED TISSUE DELIVERY
US10501404B1 (en) 2019-07-30 2019-12-10 Factor Bioscience Inc. Cationic lipids and transfection methods

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996022693A1 (en) 1995-01-24 1996-08-01 The Board Of Regents Of The University Of Texas System Self-renewing pluripotent hematopoietic stem cell compositions, methods of use, and culture systems therefor
CA2246712A1 (en) 1996-02-16 1997-08-21 The University Of Edinburgh Cytokine expressed by dia/lif-deficient embryonic stem cells for the inhibition of differentiation
US6159950A (en) * 1998-10-16 2000-12-12 Cornell Research Foundation, Inc. Method of modulating hair growth
US7005252B1 (en) 2000-03-09 2006-02-28 Wisconsin Alumni Research Foundation Serum free cultivation of primate embryonic stem cells
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
WO2002097395A2 (en) * 2001-05-31 2002-12-05 Chiron Corporation P-cadherin as a target for anti-cancer therapy

Also Published As

Publication number Publication date
DE60320599D1 (de) 2008-06-05
WO2003064463A2 (en) 2003-08-07
KR20040093699A (ko) 2004-11-08
WO2003064463A3 (en) 2003-12-11
ES2308616T3 (es) 2008-12-01
US7687266B2 (en) 2010-03-30
EP1698639B1 (en) 2008-04-23
DE60320599T2 (de) 2009-10-29
DE60304037D1 (de) 2006-05-11
JP2005536183A (ja) 2005-12-02
EP1698639A3 (en) 2006-12-06
DE60304037T2 (de) 2006-11-09
DK1698639T3 (da) 2008-07-14
US20050255573A1 (en) 2005-11-17
ATE393167T1 (de) 2008-05-15
GB0202149D0 (en) 2002-03-20
EP1470155A2 (en) 2004-10-27
EP1470155B1 (en) 2006-03-15
EP1698639A2 (en) 2006-09-06
CN1646562A (zh) 2005-07-27
ATE320446T1 (de) 2006-04-15
US20100144039A1 (en) 2010-06-10
WO2003064463B1 (en) 2004-02-12

Similar Documents

Publication Publication Date Title
DK1698639T3 (da) Pluripotensbestemmende faktorer og anvendelser deraf
MY162559A (en) Human anti-il-23 antibodies, compositions, methods and uses
ATE521658T1 (de) Silikon-polyetheramid-blockcopolymere
DK1226233T3 (da) Multipotente voksne stamceller og fremgangsmåder til isolering heraf
BRPI0507118A (pt) polipeptìdeos de interferon humano modificado e seus usos
ATE508150T1 (de) Bei raumtemperatur lanzettierbare silikonhydrogele
NZ612132A (en) Immunomodulation using placental stem cells
WO2005121331A3 (en) Truncated galnact2 polypeptides and nucleic acids
AR095541A1 (es) Muteínas de interleucina-2 (il-2) para la expansión de células t reguladoras
ECSP105739A (es) Anticuerpos de neutralización contra gdf-8
DK1616012T3 (da) Lentivirale vektorer bærende syntetiske bidirektionelle promotorer og anvendelser deraf
BRPI0620291B8 (pt) método e uso de 4,4'-diaminodifenil sulfona para produzir cepas rugosas de bactérias e composição de modulador imune
DK1474507T3 (da) Fremgangsmåder og materialer til produktion af organiske produkter i celler af Candida arter
MY147516A (en) Compositions and method of vascular injury repair cross-reference to related applications
CU20210041A7 (es) Péptidos inmunogénicos con motivos de oxidorreductasa
BR0305411A (pt) Poliisocianatos contendo grupos uretodiona pobres em monÈmeros
NO20014537D0 (no) AKT-nukleinsyrer, -polypeptider og anvendelse av disse
MX2007011381A (es) Composicion de espirulinas rica en principios activos, su proceso de obtencion y su utilizacion.
GB2385939A (en) Combination square
ATE434940T1 (de) Verfahren zur verbesserung der immunfunktion bei säugern unter verwendung von lactobacillus reuteri-stämmen
DK1465927T3 (da) BAG3-antistoffer til anvendelse til forskning, diagnostik og behandling af sygdomme, der omfatter celledød
IL150115A (en) Isolated antibody that binds to rg1 polypeptides, immunosuppressant containing this antibody, antibody uses, and methods utilizing it
WO2004090121A3 (en) Stem cells having increased sensitivity to a chemoattractant and methods of generating and using same
CY1110482T1 (el) Μεταλλαγμενο θηλαστικο εκτος του ανθρωπου για την εκφραση της υπομοναδας α6 του νικοτινικου υποδοχεα της ακετυλοχολινης και χρηση για τη διαλογη ουσιων ικανων να αλληλεπιδρουν με τον υποδοχεα αυτον
ATE290090T1 (de) Hefestamm zur prüfung der geno- und zytotoxizität komplexer umweltkontaminationen